59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
1 citations
,
April 2008 in “Progrès en Urologie” Finasteride shows promise for preventing prostate cancer, but more research is needed.
April 2019 in “Journal of Investigative Dermatology” New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.
April 2026 in “Journal of Cancer” Cepharanthine shows promise as a natural anticancer treatment.
58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
18 citations
,
October 2015 in “Journal of the European Academy of Dermatology and Venereology” Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.
5 citations
,
January 1991 in “Drugs of The Future” 15 citations
,
July 2022 in “Frontiers in Pharmacology” Cepharanthine may help treat COVID-19 by targeting similar pathways as other inflammatory diseases.
April 2011 in “The Journal of Urology” Finasteride effectively reduced priapism episodes in children with sickle cell disease without side effects.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” The combination of encorafenib and binimetinib caused few skin issues.
6 citations
,
June 2013 in “Toxicological Research” Topical Valproate is safe for human skin and unlikely to cause irritation.
September 2022 in “Concilium” Scalp cooling effectively prevents chemotherapy-induced hair loss but requires better pain management.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
23 citations
,
March 2019 in “AIDS Care” Remembering to take PrEP is the main challenge, and urine monitoring is a preferred adherence method.
12 citations
,
October 2012 in “International Braz J Urol” Finasteride effectively and safely treats recurrent priapism in children and adolescents with sickle cell disease.
July 2025 in “ALEXMED ePosters” 16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
4 citations
,
April 2018 in “Biotechnology Letters” Human growth factor 20 can boost mouse whisker growth.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
9 citations
,
June 2017 in “Pharmacological Reports” ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.
December 2023 in “Reactions weekly” December 2023 in “Reactions weekly” September 2013 in “Reactions weekly” 74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
June 2026 in “World Journal of Clinical Pediatrics” Early diagnosis and tailored treatment improve outcomes for non-nutritional rickets.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.